Details of the Drug

General Information of Drug (ID: DMPA5WD)

Drug Name
Harmine
Synonyms
Harmine; 442-51-3; 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole; Banisterine; Leucoharmine; Telepathine; Yageine; Yajeine; 7-Methoxy-1-methyl-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 7-methoxy-1-methyl-; Telepathin; Banisterin; Yagein; Harmin; 1-Methyl-7-methoxy-beta-carboline; UNII-4FHH5G48T7; 7-Methoxy-1-methyl-9H-pyrido(3,4-b)indole; Harmin hydrochloride; Harmine, 98%; Banisterine monohydrate; EINECS 207-131-4; 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-; BRN 0178813; 4FHH5G48T7; C13H12N2O; CHEBI:28121; 7-METHOXY-1-METHYL-9H-BETA-CARBOLINE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 212.25
Topological Polar Surface Area (xlogp) 3.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C13H12N2O
IUPAC Name
7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
Canonical SMILES
CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC
InChI
InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3
InChIKey
BXNJHAXVSOCGBA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5280953
ChEBI ID
CHEBI:28121
CAS Number
442-51-3
DrugBank ID
DB07919
TTD ID
D00OWF

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) TTSBVFO DYR1A_HUMAN Inhibitor [3]
Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) TT84OS6 DYRK2_HUMAN Inhibitor [3]
Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) TTV4EX0 DYRK3_HUMAN Inhibitor [3]
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [1], [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type A (MAO-A) DTT MAOA 8.14E-01 0.05 0.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
3 Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
4 Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
5 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
6 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
7 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
8 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
9 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
10 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
11 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
12 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
13 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
14 Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.